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Abstract
Background: DNA of the polyomaviruses WU (WUPyV) and KI (KIPyV) and of human bocavirus (HBoV) has been
detected with varying frequency in respiratory tract samples of children. However, only little is known about the
humoral immune response against these viruses. Our aim was to establish virus-specific serological assays and to
determine the prevalence of immunoglobulin G (IgG) against these three viruses in the general population.
Methods: The capsid proteins VP1 of WUPyV and KIPyV and VP2 of HBoV were cloned into baculovirus vectors
and expressed in Sf9 insect cells. IgG antibodies against WUPyV VP1, KIPyV VP1, and HBoV VP2 were determined by
immunofluorescence assays in 100 plasma samples of blood donors.
Results: The median age of the blood donors was 31 years (range 20 - 66 yrs), 52% were male. 89% of the
samples were positive for WUPyV IgG (median age 31 yrs, 49.4% male), 67% were positive for KIPyV IgG (median
age 32 yrs, 46.3% male), and 76% were positive for HBoV IgG (median age 32 yrs, 51.3% male). For WUPyV and
HBoV, there were no significant differences of the seropositivity rates with respect to age groups or gender. For
KIPyV, the seropositivity rate increased significantly from 59% in the age group 20 - 29 years to 100% in the age
group > 50 years.
Conclusions: High prevalences of antibodies against WUPyV, KIPyV, and HBoV were found in plasma samples of
healthy adults. The results indicate that primary infection with these viruses occurs during childhood or youth. For
KIPyV, the seropositivity appears to increase further during adulthood.
Background
Infections of the respiratory tract are a major cause of
human morbidity. They are most often caused by
respiratory viruses, which include the well-known patho-
gens respiratory syncytial virus, influenza viruses A and
B, adenoviruses, parainfluenza viruses, rhinoviruses, and
coronaviruses. In recent years, a number of unknown
viruses have been identified in the respiratory tract by
molecular methods, including the human metapneumo-
virus, several corona viruses, the human bocavirus
(HBoV), and most recently the polyomaviruses WU
(WUPyV) and KI (KIPyV) [1-4].
Initial studies on WUPyV and KIPyV have looked at
genome detection rates using polymerase chain reaction
(PCR) methods. The genoprevalences for WUPyV and
KIPyV in respiratory samples from children with acute
respiratory tract diseases were found to range from 1.1
to 7.0% [4-10] and 0.9 to 2.7% [3,6-8,11], respectively.
However, WUPyV and KIPyV DNA were found at simi-
lar frequencies in control groups without respiratory
tract disease [5,8,11]. Therefore, the clinical relevance of
WUPyV and KIPyV infections is currently unclear. In
contrast to PCR assays, serological assays for antibody
detection against HBoV are more complex to establish.
However, determining immunoglobulin (Ig) M and IgG
antibodies in appropriate serum or plasma samples
allows to define the point in time of primary infection
as well as exposure rates. One study describing the
* Correspondence: weissbrich@vim.uni-wuerzburg.de
1Institute of Virology and Immunobiology, University of Würzburg,
Versbacher Str. 7, 97078 Würzburg, Germany
Neske et al. BMC Infectious Diseases 2010, 10:215
http://www.biomedcentral.com/1471-2334/10/215
© 2010 Neske et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.seroepidemiology of polyomaviruses including WUPyV
and KIPyV in adults has recently been published [12].
HBoV is a virus of worldwide distribution. Its DNA
has been found in 1.5% to 19% of respiratory secretions
from children with acute respiratory tract diseases using
PCR [13]. Elucidation of the clinical relevance of HBoV
has been difficult because of a high co-infection rate of
HBoV DNA positive samples with other respiratory
viruses. Based on the combination of a high HBoV load
in nasopharyngeal samples (> 10
4 copies/ml) and conco-
mitant HBoV DNA detection in sera, a model has been
proposed in which HBoV is associated with acute
respiratory tract diseases but persists in the respiratory
tract for a longer period of time than other respiratory
viruses after primary infection [14]. Recent serological
studies have demonstrated evidence of primary HBoV
i n f e c t i o ni nc h i l d r e nw i t ha c u t er e s p i r a t o r yt r a c td i s -
eases, strongly indicating that HBoV is indeed a respira-
tory pathogen [15,16]. In seroprevalence studies from
Japan, the United States, China, and Germany the pro-
portions of HBoV IgG-positive samples increased with
age during infancy until reaching levels of > 80% at the
age of > 4 years [15,17-19].
In order to expand the epidemiological knowledge
about HBoV, WUPyV, and KIPyV, we expressed capsid
proteins in the baculovirus system and established an
immunofluorescence assay (IFA) for the detection of
IgG antibodies against these three viruses. We used this
system to determine the prevalence of antibodies against
HBoV, WUPyV, and KIPyV in healthy adults.
Methods
Blood donor samples
The specimens tested for WUPyV, KIPyV, and HBoV
serology consisted of 100 consecutive plasma samples of
healthy blood donors received in 2006 from the Institute
of Transfusion Medicine and Hemotherapy at the Uni-
v e r s i t yC l i n i co fW ü r z b u r g .T h em e d i a na g eo ft h e
blood donors was 31.5 years (range 20.4 - 66.3 years)
and 52% were male. The samples were screened routi-
nely for infectious diseases transmitted by blood (human
immunodeficiency virus, hepatitis B virus, hepatitis C
virus, syphilis). Remaining material was stored at -20°C
until use. The study was carried out in compliance with
the Helsinki Declaration. Informed consent of the blood
donors was obtained. According to the ethics committee
of the medical faculty at the University of Würzburg,
formal approval of the study was not necessary because
the samples were tested in an anonymised fashion.
Protein expression
The VP2 gene of HBoV was amplified from a naso-
pharyngeal aspirate using the primers BoV3446s and
BoV5113a and Pfu Polymerase (Fermentas, St. Leon
Rot, Germany) resulting in a 1667 bp PCR product
(Table 1). Similarly, the VP1 genes of WUPyV and
KIPyV were amplified from nasopharyngeal aspirates
with the primer pairs WU1673s/WU2782a and
KI1501s/KI2727a resulting in amplicons of 1109 bp
and 1226 bp, respectively (Table 1). Sequences were
submitted to GenBank with the accession numbers
FJ560720 (HBoV), EU711057 (WUPyV), and FJ647575
(KIPyV). For production of the recombinant baculo-
viruses BacWUVP1, BacKIVP1, and BacBOVP2 the LR
recombination system (Invitrogen, Karlsruhe, Ger-
many) was used according to the recommendations of
the manufacturer. Briefly, the amplicons were inserted
by TOPO cloning into the pENTR vector (Invitrogen)
and subsequently transformed in chemically competent
E.coli TOP10 cells (Invitrogen). The resulting plasmids
pBOVP2, pWUVP1, and pKIVP1 were extracted from
overnight culture with the QIAprepSpin Miniprep Kit
(Qiagen, Hilden, Germany) and sequenced by standard
techniques to confirm orientation and sequence iden-
tity of the plasmid insert. The plasmid inserts were
then transferred into baculoviral DNA by homologous
recombination based on Gateway technology and the
BaculoDirect system (Invitrogen). The resulting recom-
binant baculovirus DNA was directly transfected to
adherent Sf9 cells in one well of a six-well-plate using
Cellfectin reagent (Invitrogen). The cells were kept in
TC-100 growth medium (Lonz a ,B a s e l ,S w i t z e r l a n d )
supplemented with 10% fetal calf serum, 100 U/ml
penicillin, 100 μg/ml streptomycin, 0.25 μg/ml
Table 1 Primers used for the Amplification of WUPyV VP1, KIPyV VP1, and HBoV VP2
Primer Sequence (5’ -3 ’)
a Gene Position
b Virus
WU1673s-TOPO CACCGCCTGCACAGCAAAGC VP1 1673-1688 WUPyV
WU2782a ACATTATCCTTGTGTGTTTAGTATTGGGCC VP1 2782-2753 WUPyV
KI1501s-TOPO CACCAGCTGCACCCCGTGT VP1 1501-1519 KIPyV
KI2727a CCTTACTGAGTTTGCCACTATGCA VP1 2727-2704 KIPyV
BoV3446s-TOPO CACCTCTGACACTGACATTCAAGAC VP2 3446-3466 HBoV
BoV5113a AGGAGGAACTTGTAAGCAGAAGC VP2 5113-5091 HBoV
a Nucleotides added for directional cloning are underlined.
b Positions according to GenBank accession number EU711057 (WUPyV), NC_009238 (KIPyV), and DQ000496 (HBoV).
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Page 2 of 7amphotericin B, and 100 μM ganciclovir as selective
reagent. After five days, the cell culture supernatant
was collected and used to infect fresh Sf9 cells. This
procedure was repeated twice, resulting in the superna-
tant of passage 4 (P4), which was finally collected and
stored at 4°C for further use.
Protein expression was confirmed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and immunoblotting. To this end, Sf9 cells at approxi-
mately 80% confluence were inoculated with recombi-
nant virus of P4. The cells were observed daily until at
least 80% of the cells displayed a cytopathic effect,
which typically happened after seven days. Subse-
quently, the cell culture supernatant was collected and
centrifuged with 3400 g at 4°C for 5 min to remove
cells and large debris. The samples were separated by
10% SDS-PAGE and blotted on a nitrocellulose mem-
brane by standard procedures. After blocking, immu-
nodetection was performed with HRP-conjugated
mouse-anti-V5-antibody (Invitrogen) at a concentra-
tion of 188 ng/ml. Bands were visualised by Super-
Signal West Pico chemiluminescence substrate (Pierce,
Rockford, USA). Uninfected Sf9 cells were used as
negative control.
Immunofluorescence assay
Sf9 cells were inoculated with recombinant baculo-
viruses and observed daily until approximately 80% of
the cells displayed a cytopathic effect. The cells were
harvested and centrifuged for 5 min at 1000 g. The
supernatant was discarded and the cell pellet was
washed three times in phosphate buffered saline (PBS).
The Sf9 cells were spotted on glass slides, air dried,
f i x e dw i t hc o l da c e t o n ea n ds t o r e da t- 2 0 ° Cu n t i lu s e .
Slides with uninfected Sf9 cells were prepared in the
same manner and were used for control staining to
detect anticellular antibodies. One spot each with Sf9
cells expressing WUPyV VP1, KIPyV VP1, or HBoV
VP2 and one spot with uninfected Sf9 cells were incu-
bated with a 1:10 dilution of each plasma sample for 2
h at 37°C. Subsequently, the slides were washed twice
for 5 min with PBS containing 0.1% Tween 20 fol-
l o w e db yas h o r tr i n s ei nP B Sw i t h o u tT w e e n2 0 .N e x t ,
the slides were incubated with a 1:40 dilution of fluor-
esceine-conjugated goat-anti-human-IgG (Invitrogen)
and a 1:80 dilution of evans blue (Mast Diagnostik,
Reinfeld, Germany) for 1 h at 37°C. After another
washing step as described above, coverslips were
mounted for immunofluorescence microscopy. The
slides were independently read by two experienced
investigators. Plasma samples, which exhibited a vesi-
cular fluorescence adjacent to the membrane of Sf9
cells, were recorded as antibody positive, if no staining
of the control cells was detected.
Absorption test
For the absorption test, three plasma samples were
selected that were positive for antibodies against
WUPyV, KIPyV, and HBoV. Sf9 cells infected with each
of the recombinant baculoviruses (BacWUVP1, BacK-
IVP1, BacBoVP2) were harvest e df r o ms m a l lf l a s k sa n d
resuspended in 500 μl PBS. The suspensions were soni-
cated for 10 s on ice with a sonicator (Branson Sonifier
250). Each of the three plasma samples was diluted 1:5
in each of the cell lysates. After a 6 h of incubation on
ice, the samples were centrifuged at 1400 g for 5 min
and the supernatants were diluted in PBS to a final
sample concentration of 1:10. Twofold dilution series
ranging from 1:10 to 1:1280 of the absorbed and unab-
sorbed plasma samples were tested in parallel by IFA as
described above.
Statistical analysis
Statistical analysis was carried out using GraphPad
Prism version 3.0c for Mac (GraphPad Software, San
Diego, USA) and SPSS version 16 for windows (SPSS,
Chicago, USA).
Results
Capsid proteins of WUPyV, KIPyV, and HBoV were
expressed by infection of Sf9 cells with the recombinant
baculoviruses BacWUVP1, BacKIVP1, and BacBOVP2.
As antibodies against these proteins are not yet avail-
able, the correct size of the expressed proteins was con-
firmed by SDS-PAGE and immunoblotting using an
anti-V5 antibody. The V5-epitope is located upstream of
the inserted gene in the baculovirus DNA. A band of
the expected size (~46 kDa for WUPyV and KIPyV
VP1; ~66 kDa for HBoV VP2) was observed for all
recombinant baculoviruses, whereas no band was
observed in the uninfected control (Figure 1).
T od e t e r m i n et h ef r e q u e n c yo fp a s te x p o s u r ew i t h
WUPyV, KIPyV, and HBoV in healthy adults, 100 blood
donor plasma samples were tested for the presence of
IgG against WUPyV VP1, KIPyV VP1, and HBoV VP2
using an IFA based on Sf9 cells infected with the recom-
binant baculoviruses (Figure 2). All samples were also
tested by IFA using uninfected Sf9 cells. No positive
reaction with cellular antigens was observed in any of
the samples. In order to further confirm the specificity
of positive IFA results, three plasma samples were stu-
died in an absorption assay. Antibody titers were deter-
mined before and after absorption with lysates of Sf9
cells infected with recombinant baculoviruses. A signifi-
cant titer decrease was only observed after absorption
with the matching Sf9 cell lysate (Table 2). There
was no indication of antibody cross-reaction between
Sf9 cells infected with BacWUVP1, BacKIVP1, and
BacBOVP2.
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Page 3 of 7Figure 1 Confirmation of expression of recombinant proteins. Sf9 cells were infected with recombinant baculoviruses BacWUVP1, BacKIVP1,
and BacBoVP2. Uninfected Sf9 cells served as negative control. After SDS-PAGE and immunoblot, proteins were visualised by staining with anti-
V5 antibody. The expected protein sizes are ~46 kDa (WUPyV and KIPyV VP1) and ~66 kDa (HBoV VP2).
Figure 2 IFA for the detection of IgG antibodies against WUPyV VP1, KIPyV VP1, and HBoV VP2. Sf9 cells infected with recombinant
baculoviruses were incubated with plasma samples of healthy blood donors. Bound antibodies were visualised with FITC-labelled anti-human
IgG. Representative examples of positive and negative plasma samples are shown for each of the three antigens.
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WUPyV VP1 IgG, 67% were positive for anti-KIPyV
VP1 IgG, and 76% were positive for anti-HBoV VP2
IgG. Neither the median age nor the gender distribution
of the antibody positive samples were significantly dif-
ferent from the total population for any of the three
viruses tested (Mann-Whitney test and Fisher’se x a c t
test, respectively; Table 3). For WUPyV and HBoV,
there were no significant differences of the seropositivity
rates with respect to age groups. For KIPyV, the seropo-
sitivity rate increased significantly from 58,7% in the age
group 20 - 30 years to100% in the age group > 50 years
(p = 0.026; chi-square test for trend; Figure 3).
Table 4 shows the number of samples grouped by
individual results for WUPyV, KIPyV, and HBoV IgG.
One percent of the samples were negative for all three
viruses and 50% were positive for all three viruses. No
obvious cross-reaction between the three antibody speci-
ficities was apparent.
Discussion
Using IFA based on insect cells expressing capsid pro-
teins of WUPyV, KIPyV, and HBoV, we studied the ser-
oprevalence of these viruses in plasma samples of
healthy adults. We found high rates of positive IgG anti-
bodies against all three viruses: 89% for WUPyV, 67%
for KIPyV, and 76% for HBoV. Our data on seropreva-
lence for WUPyV and KIPyV are somewhat higher than
reported in a recent study from the United States,
which found seroprevalences of 54.1% to 55.3% for
KIPyV and 67.4% to 70.9% for WUPyV in the age
groups from 21 to 70 years of North American blood
donors [12]. In contrast to our findings, a rising preva-
lence for KIPyV IgG in adults was not observed. Further
studies are necessary in order to determine whether
there may be regional differences in the KIPyV epide-
miology. Taken together, the data of Kean et al. and of
our study indicate that WUPyV and KIPyV have a wide-
spread distribution similar to the well-known polyoma-
viruses BKV and JCV. Also in agreement with BKV and
JCV epidemiology, primary exposure seems to occur
mainly in childhood and youth. Primary BKV infection
has been reported to occur mainly in the first decade of
life leading to a seroprevalence of 65% to 90% at the age
of 10 (reviewed in [20]). The JCV seroprevalence in
adults has been found between 44% and 97%. Whereas
some studies reported a time frame for primary JCV
infection similar to BKV infections, others showed a
continuing rise of the JCV seroprevalence during adult-
hood (reviewed by [20]).
VP1 is the major capsid protein of polyomaviruses.
Several studies on BKV and JCV serology have used this
protein successfully in enzyme immunoassays, immuno-
blots, or IFA [21-24]. Therefore, we decided to use
expression of VP1 proteins to establish IFAs for the
detection of WUPyV and KIPyV IgG. In the study by
Kean et al., WUPyV and KIPyV antibodies were deter-
mined by an enzyme immunoassay based on bacterially
expressed VP1 capsomeres [12].
Validation of these IFA was limited by the lack of
defined serum samples that could be used to determine
assay sensitivity and specificity. By testing selected study
samples before and after absorption with lysates of Sf9
cells that were infected with different recombinant bacu-
loviruses, we were able to exclude general cross reactiv-
ity between WUPyV and KIPyV. Furthermore, we
excluded anticellular reactivity of the plasma samples by
performing an IFA with uninfected Sf9 cells. Therefore,
we are confident that our serological data are reliable.
Comparison of different serological methods and anti-
gen preparations as well as sample exchange will be use-
ful to further validate the assays for WUPyV and KIPyV
antibody determination.
As to HBoV, the adult seroprevalence of 76% in our
study is slightly lower than in previous studies from
Japan, the United States, and Germany, which reported
HBoV IgG antibody prevalence of 94%, 86%, and 94%,
respectively [15,17,19]. The total number of adult
Table 2 Antibody titers before and after absorption with
lysates of virus capsid protein expressing Sf9 cells
Antibody titers after
absorption with lysates
of Sf9 cells expressing
a
Plasma sample and
antibody
Titers prior to
absorption
WUPyV
VP1
KIPyV
VP1
HBoV
VP2
Patient 1
Anti-WUPyV 1:80 1:20 1:80 1:40
Anti-KIPyV 1:80 1:80 1:20 1:80
Anti-HBoV 1:160 1:160 1:160 1:10
Patient 2
Anti-WUPyV 1:40 1:10 1:20 1:20
Anti-KIPyV 1:320 1:320 1:40 1:320
Anti-HBoV 1:320 1:640 1:640 1:40
Patient 3
Anti-WUPyV 1:160 1:40 1:160 1:80
Anti-KIPyV 1:160 1:80 1:20 1:160
Anti-HBoV 1:320 1:320 1:320 1:10
a Antibody titers obtained with homologous Sf9 cell lysates are shown in bold.
Table 3 IgG seroprevalence for HBoV VP2, WUPyV VP1,
and KIPyV VP1 in 100 healthy blood donors
group n Median age in years Male
All samples 100 31.5 52%
WUPyV IgG positive 89 31.2 49%
KIPyV IgG positive 67 32.1 46%
HBoV IgG positive 76 31.8 51%
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and 299, respectively). Whether methodological issues
or differences in the study populations account for the
lower seroprevalence observed in this study, could be
addressed by method comparisons and sample
exchange.
We chose the HBoV VP2 gene for recombinant
expression on the basis of current knowledge about
immunodominant antigens of parvovirus B19, which
belongs to the same virus family as HBoV. Previous stu-
dies on HBoV serology have used IFA based on VP1-
expressing insect cells [15], enzyme immunoassay based
on VP2 purified from insect cells [17,18], immunoblot
based on VP2 and the unique region of VP1 expressed
in E. coli [16], and enzyme immunoassay based on VP2
virus-like particles [19]. In the study of Kantola et al., a
higher immunoreactivity was demonstrated for HBoV
VP2 than for the unique part of HBoV VP1. Overall, the
VP2 protein seems to be suitable for use in serological
assays. However, a comparison of the VP1 and VP2 pro-
tein has not yet been performed.
Limitations of the HBoV IFA validation are similar to
the limitations described for the WUPyV and KIPyV
IFA. Results of a control IFA using uninfected Sf9 cells
and of pre-absorption experiments suggest that the posi-
tive HBoV IgG results are specific. Recently, novel boca-
viruses related to HBoV have been described in humans
[25,26]. If there are cross-reactions between antibodies
against the different HBoV types is not known at pre-
sent and needs to be further investigated.
In this seroepidemiological study, only IgG antibodies
were determined. Evidently, the IFAs used in this study
m a ye a s i l yb em o d i f i e df o rt h ed e t e r m i n a t i o no fI g M
antibodies. IgG and IgM serology applied on appropriate
sample collections will allow to determine the point in
time of primary infection. Information on this issue is
Figure 3 Age distribution of virus-specific IgG antibodies. The seroprevalence for WUPyV and HBoV did not differ significantly between age
groups (p = 0.855 and p = 0.175, respectively). For KIPyV, a significant rise of seroprevalence rates was observed with increasing age (p = 0.026).
Table 4 Results of WUPyV, KIPyV, and HBoV IgG IFA of
individual samples
Result of HBoV
IgG IFA (n)
Results of WUPyV and KIPyV IgG IFA Negative Positive Total (n)
WUPyV and KIPyV negative 1 3 4
WUPyV negative, KIPyV positive 1 6 7
WUPyV positive, KIPyV negative 12 17 29
WUPyV and KIPyV positive 10 50 60
Total 24 76 100
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WUPyV, KIPyV, and HBoV.
Conclusions
Antibodies against HBoV, WUPyV, and KIPyV were
found at high rates in sera of healthy German adults.
These results suggest that primary infections with these
viruses occur mainly during childhood and youth. For
KIPyV, the seropositivity appears to increase further
during adulthood.
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